Cytotoxic, Anti-Proliferative and Apoptosis Activity of L-Amino Acid Oxidase from Malaysian Cryptelytrops purpureomaculatus (CP-LAAO) Venom on Human Colon Cancer Cells

Syafiq Asnawi Zainal Abidin, Pathmanathan Rajadurai, Md. Ezharul Hoque Chowdhury, Iekhsan Othman and Rakesh Naidu *

Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, 47500 Selangor Darul Ehsan, Malaysia; syafiqnawi@gmail.com (S.A.Z.A.); drpathma@gmail.com (P.R.); md.ezharul.hoque@monash.edu (M.E.H.C.); iekhsan.othman@monash.edu (I.O.)
* Correspondence: kdrakeshna@hotmail.com; Tel.: +60-35-514-6345

Academic Editor: Jean-Marc Sabatier
Received: 20 April 2018; Accepted: 31 May 2018; Published: 8 June 2018

Abstract: The aim of this study is to investigate the potential anti-cancer activity of L-amino acid oxidase (CP-LAAO) purified from the venom of Cryptelytrops purpureomaculatus on SW480 and SW620 human colon cancer cells. Mass spectrometry guided purification was able to identify and purify CP-LAAO. Amino acid variations identified from the partial protein sequence of CP-LAAO may suggest novel variants of these proteins. The activity of the purified CP-LAAO was confirmed with o-phenyldiamine (OPD)-based spectrophotometric assay. CP-LAAO demonstrated time- and dose-dependent cytotoxic activity and the EC50 value was determined at 13 µg/mL for both SW480 and SW620 cells. Significant increase of caspase-3 activity, reduction of Bcl-2 levels, as well as morphological changes consistent with apoptosis were demonstrated by CP-LAAO. Overall, these data provide evidence on the potential anti-cancer activity of CP-LAAO from the venom of Malaysian C. purpureomaculatus for therapeutic intervention of human colon cancer.

Keywords: L-amino acid oxidase; Cryptelytrops purpureomaculatus; cytotoxicity; apoptosis; human colon cancer cells

1. Introduction

Cancer remains as one of the major causes of death and accounts for seven million deaths worldwide [1]. Colon cancer represents the second highest cause of cancer-related deaths in the United States with a death toll estimated around 50,830 in 2013 [2]. It was classified as second most frequent cancer in Malaysia, representing 12.3% of the population and trailing behind breast cancer which accounts for 18.1% of the population. The survival rate of colon cancer patients was lower in Malaysia compared to Singapore, United Kingdom, and United States [3]. Therefore, continued research into the treatment and management of the disease remains critical. Currently, various approaches have been used for cancer treatment, including colorectal cancer, for instance via surgery, chemotherapy, radiotherapy, and the much recent targeted therapy that involves immunotherapy and epigenetic therapy [2,4]. Standard regimens in treating colon cancer are the administration of cytotoxic chemotherapy drugs such as FOLFOX (folinic acid, fluoroacil, and oxaliplatin), FOLFIRI (folinic acid, fluoroacil, and irinotecan), and FOLFOXIRI (folinic acid, fluoroacil, oxaliplatin, and irinotecan) [5]. However, application of chemotherapeutic drugs has several known side effects including skin toxicity, nausea, vomiting, and hair loss. There are several novel therapeutic agents being developed for the treatment of colon cancer such as cancer stem cell inhibitors, BRAF and PI3K inhibitors, and the
anti-RAS reovirus Reolysin® [5]. Additionally, nature provides a rich source for new and alternative cancer therapeutic drug candidates due to the mega-biodiversity of natural chemical compounds or protein and polypeptides found in millions of flora and fauna species.

Malaysia’s rich natural resources may hold answers for novel and effective anti-cancer drug candidates. Snake venom is one of many abundant natural resources that can be obtained from locally found snakes in the country. The complexity and mixture of multiple compounds and proteins/polypeptides found in the snake venom, which contribute towards the venom action in killing and immobilizing its prey, can be an important source of therapeutic compounds or proteins. Snake venom L-amino acid oxidase (LAAO) have been studied for its anti-cancer potential through cytotoxic and apoptotic activity in various cancer cell lines including human promyelocytic leukemia cells (HL-60) [6–8], human T cell leukemia (Jurkat) [8] human cervical adenocarcinoma (HeLa) [9,10], human lung adenocarcinoma (A549) [11], human breast adenocarcinoma (MCF-7) [12], human gastric and colon adenocarcinoma (MKN45 and RKO) [13], and Ehrlich ascites tumor cells [7]. The authors noted that the cytotoxic effects were mainly driven by the production of H2O2 by LAAO activity. Despite many studies on the anti-cancer potential of LAAO, none has been performed on LAAO from *C. purpureomaculatus* (CP-LAAO) and human colon cancer cells. Therefore, the present study is aimed to investigate the cytotoxic activity, anti-proliferative, and induction of apoptosis by CP-LAAO against primary and metastatic human colon cancer cells.

2. Results

2.1. Cytotoxic Screening of *C. purpureomaculatus* Crude Venom

The crude venom of *C. purpureomaculatus* demonstrated cytotoxic activity in all cell lines with EC50 values of 29.43 µg/mL, 23.19 µg/mL, and 15.99 µg/mL in SW480, SW620, and CCD-18co, respectively (Figure 1, Table 1).

**Figure 1.** The cytotoxic effects of *C. purpureomaculatus* crude venom at different concentrations on SW480, SW620, and CCD-18co cell lines compared to untreated sample (control) after 72 h incubation. Data are presented as mean ± SD from three independent experiments. Percentage of cell viability and comparison between datasets were statistically analyzed using One Sample t-tests. Asterisks indicate statistically significant differences between the means of the values obtained with treated vs. untreated cells (*p < 0.05, ***p ≤ 0.001 ****p < 0.0001).
Table 1. Average EC$_{50}$ from SW480, SW620, and CCD-18co treated with *C. purpureomaculatus* crude venom for 72 h.

| Cell Lines | EC$_{50}$ (µg/mL) ± SD |
|------------|------------------------|
| SW480      | 29.43 ± 0.48           |
| SW620      | 23.19 ± 1.57           |
| CCD-18co   | 15.99 ± 1.20           |

2.2. Purification of *C. purpureomaculatus* LAAO

CP-LAAO were purified from the crude venom following a bioassay guided and mass spectrometry approach. Subfraction 9 was selectively cytotoxic against the human colon cancer cells and therefore were chosen for further purification. LC-MS/MS analysis of the collected fraction identified CP-LAAO from subfraction 9 as pure since there were no other proteins detected from the fractions (Table S1). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the collected subfraction demonstrated a single band confirming its purity (Figure S1). To the best of our knowledge, CP-LAAO from *C. purpureomaculatus* has not been previously characterized. CP-LAAO was determined to be homologous with LAAO from Bothriechis, Calloselasma, Vipera, and Cerastes genus (Table S1). Protein identification and automated de novo sequencing were able to determine the partial protein sequence of CP-LAAO by comparing against homologous sequences from other snake species determined from the database. De novo sequencing by LC-MS/MS of the isolated CP-LAAO showed that there were three amino acid substitutions at position 55 (isoleucine replaced by arginine), 286 (glutamate replaced by lysine), and 416 (glutamine replaced by proline), compared to homologous LAAO sequences (Table S2, Figure S2).

2.3. L-amino Acid Oxidase Assay

LAAO activity of *C. purpureomaculatus* crude venom and CP-LAAO was determined by o-phenyldiamine (OPD)-based microplate spectrophotometric assay. The Vmax value of the purified LAAO at every substrate (l-leucine) concentration was obtained from kinetic readings of the assay and was used to plot the Michaelis-Menten model of enzyme activity (velocity) against substrate concentration. V$_{\text{max}}$ and K$_{m}$ values of 16.77 mM/min and 4.376, respectively, were obtained from the model (Figure 2).

![Figure 2](image-url)
2.4. Cytotoxicity and Anti-Proliferative Activity of CP-LAAO

Significant inhibition of cell proliferation was demonstrated when treated with 20 µg/mL and 40 µg/mL of CP-LAAO at 72 h in both SW480 (Figure 3A) and SW620 (Figure 3B) cells with cell viability of approximately 20–30%. Significant reduction of cell viability was noted at 24 h in SW480 cells treated with 20 µg/mL of CP-LAAO, but it was not significant at 48 h. In SW620 cells, treatment with 40 µg/mL CP-LAAO demonstrated significant reduction of cell viability at both 24 and 48 h. EC$_{50}$ value of 13 µg/mL was obtained from the treatment of CP-LAAO in both cell lines at 72 h. The EC$_{50}$ value of the normal colon cells was approximately 1.1 fold higher compared to SW480 and SW620. Overall, cytotoxic activity of CP-LAAO on the cancer cells were slightly higher in the cancer cells compared to the normal cells. However, the selective index (SX) values were noted at more than 100 (Table 2), which might still indicate a selective cytotoxic effect on the cancer cells.

![Figure 3](image-url)

*Figure 3.* The anti-proliferative effects of purified CP-LAAO on SW480 (A) and SW620 (B), at 24, 48, and 72 h. The results are expressed as means of percentage cell viability over time. Experiments were performed in triplicates and results were compared between three independent experiments. ** p ≤ 0.01 and *** p ≤ 0.001, **** p ≤ 0.0001 indicates statistically significant differences between the means of values obtained with treated vs untreated cells.

**Table 2.** EC$_{50}$ and selective index (SX) values of SW480, SW620, and CCD-18co treated with CP-LAAO at 72 h.

| Cell Lines | EC$_{50}$ Values (µg/mL) ± SD | Selective Index Value (SX) |
|------------|-------------------------------|-----------------------------|
| SW480      | 13.56 ± 0.58                  | 110.47                      |
| SW620      | 13.17 ± 0.77                  | 113.74                      |
| CCD-18co   | 14.98 ± 2.67                  | -                           |
2.5. Apoptotic Activity Induced by CP-LAAO on SW480 and SW620 Cells

Morphological changes associated with apoptosis on SW480 and SW620 cells were assessed using annexin V-FITC and propidium iodide staining. Cells were quantified and grouped into viable, apoptotic, and necrotic cells. CP-LAAO treatment on SW480 (Figure 4A–C) and SW620 (Figure 4D–F) cells resulted in a significant decline of viable cell population at 24 h by 10–20% at both doses of 13 µg/mL and 26 µg/mL of the treatment concentration. Percentage of viable cells further declined by 30–40% in both SW480 and SW620 at 48 h when treated with 13 µg/mL and 26 µg/mL of CP-LAAO. Significant increases of apoptotic cells were demonstrated following 24 h of CP-LAAO treatment, whereby, approximately 20–25% of cells had undergone apoptosis in both SW480 and SW620 cells at treatment concentrations of 13 µg/mL and 26 µg/mL. Forty-eight hours of post-treatment with 13 µg/mL of CP-LAAO demonstrated further increases of apoptotic cells in SW480 (approximately 30%) and SW620 (approximately 38%) cells. When the treatment dose was increased to 26 µg/mL at 48 h, the apoptotic cell population in SW480 and SW620 was approximately 38% and 30%, respectively. However, a significant increase of necrotic cells to approximately 18–24% of the total cell population was demonstrated following treatment with 13 µg/mL of CP-LAAO in SW480 and SW620 cells at 48 h. In SW620 cells, the necrotic cell population was significantly increased to approximately 34% of the total cell population when treated with 26 µg/mL of CP-LAAO at 48 h. Seventy-two hours of 13 µg/mL of CP-LAAO treatment in both cell lines caused further reductions of the viable cell population to approximately 20–30%, while the apoptotic cell population remained at approximately 30–35% of the total cell population. Necrotic cell population continued to increase significantly at 72 h of 13 µg/mL treatment to 35–40% of the total cell population in both cell lines. No data was obtained at 72 h when the dose was increased to 26 µg/mL. In summary, CP-LAAO appeared to induce apoptosis at 24 h after treatment for SW480 and SW620 cells in a time- and dose-dependent manner. The percentage of necrotic cells at 24 h was also relatively low compared with other time points.

![Figure 4. Cont.](image-url)
When compared to untreated cells, caspase-3 activity in both cell lines was significantly higher at 72 h (Figure 5A,B). However, there was no significant increase of caspase-3 activity at 72 h in both cell lines when compared to untreated cells.

2.6. CP-LAAO on Caspase-3 Activity of Treated SW480 and SW620 Cells

Caspase-3 activity peaked at 48 h in both SW480 and SW620 cells when treated with 13 µg/mL and 26 µg/mL of CP-LAAO in a dose-dependent manner. The caspase-3 activity at 48 h was significantly higher compared to the caspase-3 activity at 24 h in SW480 (1.5–2 fold higher) and SW620 (2.5–3 fold higher) (Figure 5A,B). However, there was no significant increase of caspase-3 activity at 72 h in both cell lines when compared to untreated cells.
Figure 5. Caspase-3 activity in CP-LAAO-treated SW480 (A) and SW620 (B) cells measured at 24, 48, and 72 h. Experiments were performed in duplicates and results compared between three independent experiments (n = 3). Results were analyzed using One Sample t-tests between the ratios of means of caspase-3 activity of treated samples over untreated samples. Asterisks indicate statistically significant data (*** p ≤ 0.001, **** p ≤ 0.0001). Error bars represent standard deviation (SD).

2.7. Quantification of Bcl-2 Protein Concentration on CP-LAAO Treated SW480 and SW620 Cells

Treatment of SW480 and SW620 cells with 13 µg/mL and 26 µg/mL of CP-LAAO demonstrated a significant and progressive reduction of Bcl-2 concentration from 24 to 72 h of post-treatment (Figure 6A,B).
The partial sequences were able to highlight several amino acid variants in the peptide sequence. Based on the de novo sequencing of the isolated CP-LAAO using LC-MS/MS and PEAKS software, we were able to construct the partial protein sequence of the protein. The peptide sequences were found to be homologous to proteins from other viper/pit viper species from the large database in SwissProt/UniProt (2584 reviewed proteins, 64,430 unreviewed proteins) [19]. This was because LAAO from C. purpureomaculatus has never been identified and therefore the information was not available in the database.

From de novo sequencing of the isolated CP-LAAO using LC-MS/MS and PEAKS software, we were able to construct the partial protein sequence of the protein. The peptide sequences were found to be homologous to proteins from other viper/pit viper species from the large database in SwissProt/UniProt (2584 reviewed proteins, 64,430 unreviewed proteins) [19]. This was because LAAO from C. purpureomaculatus had never been identified and therefore the information was not available in the database.

The partial sequence of CP-LAAO was constructed by comparing the identified peptides from LC-MS/MS and de novo sequencing with the homologous protein from other viper/pit viper species. The partial sequences were able to highlight several amino acid variants in the peptide sequence. Based
on the CP-LAAO partial sequence, there were three amino acid substitutions at positions 55, 286, and 416, where arginine replaced isoleucine, lysine replaced glutamate, and proline replaced glutamine, respectively. The significance of the substitutions at positions 55 and 416 is unknown; however, Lys-286 may be essential to the LAAO cofactor, flavo-adenine-nucleotide (FAD), binding domain. This is supported by sequential evidence provided in UniProt database of LAAO from other species such as *Calloselasma rhodostoma* [P81382 OXLA_CALRH], *Cerastes cerastes* [X2CV5 OXLA_CERCE], and *Trimeresurus stejnegeri* [Q6WP39 OXLA_TRIST] that contain FAD binding sites at nearby positions [20].

FAD is a non-covalently bound cofactor of most snake venom LAAO and is essential in the production of hydrogen peroxide (H$_2$O$_2$) during the enzymatic reaction of LAAO [21,22]. It is possible that changes on FAD site could affect the cytotoxic activity of LAAO on cancer cells since the production of H$_2$O$_2$ from the enzyme was identified to contribute towards cytotoxicity and apoptotic activity in several cell lines, such as HL60 (human promyelocytic cell), HeLa (cervical cancer cells), MM6 (human monocytic cell), and human leukemia T-cells [7–9,23]. The purified CP-LAAO was demonstrated to be active based on the activity assay performed against substrate L-leucine in this study.

Anti-proliferative assay was performed over three time points to determine the potential of CP-LAAO in inhibiting SW480 and SW620 cell growth. CP-LAAO demonstrated significant cytotoxic activity in SW480 and SW620 cells at 72 h from 20 µg/mL onwards, compared with CCD-18co. EC$_{50}$ value of 13 µg/mL was obtained from the treatment of CP-LAAO in both SW480 and SW620. It is believed that the present data represents the first evidence of CP-LAAO cytotoxic activity in human colon cancer cells. Several LAAOs from other snake species have been isolated and demonstrated cytotoxic activity to cancer cell lines including MCF-7 [12], MKN-45 [13], A549 [11], HL-60 [7,8], and HeLa [9]. The EC$_{50}$ value of CP-LAAO obtained in this present study was higher compared with LAAOs isolated from *Bothrops moojeni*, which showed an EC$_{50}$ value of 8 µg/mL in HL-60 cells [7]. However, CP-LAAO had higher cytotoxic activity than LAAOs isolated from *Bothrops atrox* and *Agkistrodon acutus*, which demonstrated EC$_{50}$ values of 50 µg/mL in HL-60 cells and 20 µg/mL in HeLa cells, respectively [8,9]. Additionally, the cytotoxicity of CP-LAAO was influenced by the dose and treatment length.

Apoptosis pathways are often dysregulated in the progression of cancerous cells [24]. Therefore, targeting the apoptosis mechanism is deemed important in the development of effective anti-cancer therapeutic agents. In this present study, several assays were utilized to determine the induction of apoptosis via morphological and biochemical assessments. Quantitative analysis of the cells was performed based on the morphological features to investigate the apoptotic cell population. A significant increase in the apoptotic cell population was observed from SW480 and SW620 cells treated with CP-LAAO at 24 h and peaked at 48 h. However, CP-LAAO treatment caused a significant increase of necrosis, especially in SW620, where it reached approximately 20% and 30% of the cell population at 48 h of 13 µg/mL and 26 µg/mL of treatment concentration, respectively. Taken together, the quantitative morphological assessment of treated SW480 and SW620 cells indicate that CP-LAAO had the capability of inducing apoptosis in a time- and dose-dependent manner.

The induction of apoptosis and the downstream signaling is mediated by several important proteins such as caspase-3 and Bcl-2 [25]. The results clearly demonstrated that caspase-3 activity was significantly increased in both colon cancer cell lines (SW480 and SW620) over the basal level of untreated (control) cells after exposure with CP-LAAO at 24 h and peaked at 48 h. Strikingly, there was no significant increase of caspase-3 activity after 72 h from all treatment in both cell lines when compared with the untreated cells. These results demonstrated a caspase-3-dependent apoptosis in SW480 and SW620 cells. Therefore, it could be suggested that CP-LAAO was able to induce apoptosis in both cell lines. The ability of LAAO to induce apoptosis in human cancer cell lines was evident in HeLa [15,26], MM6 [12], Jurkat cells [27], and RBR 17T (human malignant glioma cells) [28]. Furthermore, activation of caspase-3 were often demonstrated in cancer cell lines upon LAAO exposure [8,26,29]. Besides caspase-3, Bcl-2 is a key protein in apoptosis induction. Bcl-2 regulates mitochondrial membrane permeability and integrity, in addition to suppression of
cytochrome c release [30,31]. It was demonstrated that overexpression of Bcl-2 may protect the cancer cell from cell death while decrease in expression may trigger apoptosis [32]. In this present study, treatment of CP-LAAO on SW480 and SW620 cells resulted in a significant reduction of Bcl-2 cellular protein concentration in a dose- and time-dependent manner. The present findings are supported by several studies that demonstrated reduced expression of Bcl-2 proteins in HepG2 (human hepatocyte carcinoma) and HL-60 (human promyelocytic leukemia) cells when treated with LAAO [33]. Therefore, the present findings suggest that CP-LAAO induces apoptosis by decreasing Bcl-2 expression and increased caspase-3 activity.

4. Materials and Methods

4.1. Snake Venom

Crude C. purpureomaculatus venom were obtained from Mr. Zainuddin Ismail, a private and licensed snake handler from Perlis, Malaysia. The venom was carefully collected in a sterile container covered with parafilm and kept on ice during transportation. Prior to usage, the venom was frozen at −80 °C followed by lyophilization process. Dried venoms were weighed, labelled, and stored at −20 °C prior to use.

4.2. Protein Quantification by Bichinchoninic Acid Assay (BCA Assay)

Protein quantification was performed with Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) and as instructed by the manufacturer’s protocol. Serially diluted bovine serum albumin (BSA) was used as a standard (60–2000 µg/mL). The absorbance was measured at 562 nm with a microplate spectrophotometer reader (BioTek™ EON™ Microplate Spectrophotometers, Fisher Scientific, USA).

4.3. Preparation of Crude Venom and Purified CP-LAAO for Cytotoxic and Apoptosis Evaluation

Crude venom and purified CP-LAAO were quantified using a Pierce© BCA assay kit. The crude venom was serially diluted in the appropriate media at a concentration range of 1.56 µg/mL, 3.125 µg/mL, 6.25 µg/mL, 12.5 µg/mL, 25 µg/mL, 50 µg/mL, and 100 µg/mL (two-fold dilution) prior to cell treatment. CP-LAAO was subjected to caspase-3 and Bcl-2 assays and was prepared in the appropriate cell culture media at the following concentrations; CP-LAAO; 13 µg/mL (1 × EC50) and 26 µg/mL (2 × EC50) in SW480 and SW620. Similar concentrations were used for CP-LAAO for morphological assessment using Annexin-V and propidium iodide.

4.4. Cell Culture and Maintenance

Primary (SW480, ATCC® CCL-228™) and metastatic (SW620, ATCC® CCL-227™) colon cancer cell lines and normal colon cell line (CCD-18co, ATCC® CRL-1459™) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). SW480 and SW620 cells were maintained in Leibovitz L-15 medium (Corning Life Sciences, Corning, NY, USA) supplemented with 10% fetal bovine serum and 1% antibiotics; penicillin and streptomycin, in a 37 °C incubator without CO2. CCD-18co cells were maintained in Eagles Minimum Essential Medium (EMEM) (Corning Life Sciences, USA) supplemented with 10% fetal bovine serum and 1% antibiotics, in a 37 °C incubator with CO2. Cells were frequently monitored to ensure a normal and consistent morphology. While maintaining proper aseptic techniques, the cells were subcultured every 2–3 days or upon 90% confluency and the culture medium replenished within a biosafety cabinet (Labculture © Class II, Type A2 Biological Safety, Esco Technologies Inc., Horsham, PA, USA).

4.5. Cytotoxic and Anti-Proliferative Assay

The cells were seeded in a flat-bottomed microtitre 96-well plates (Nunc, Roskilde, Denmark) at a concentration of 70,000 cells/mL together with appropriate culture media in triplicates and
incubated for 24 h at 37 °C in a humidified incubator to allow the cells to adhere to the bottom of the wells. After 24 h, the media was aspirated and replaced with fresh media containing different treatment doses of the crude venom or purified CP-LAAO. Control cells were treated with only double distilled water. The cells were incubated for 72 h at 37 °C, with and without 5% CO₂ for CCD-18co and SW480/620, respectively. To assess the cell viability, colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was performed. Briefly, the medium was aspirated and 100 µL of medium with MTT solution (0.5 mg/mL in PBS) was added to every well and incubated for 4 h at 37 °C. The MTT was aspirated and 100 µL dimethyl sulfoxide (DMSO, Molecular Biology Grade, Sigma-Aldrich, St. Louis, MO, USA) was added into each well to dissolve the formazan crystals. The absorbance of the blue formazan was read at 570/650 nm wavelengths using a microplate spectrophotometer (BioTek™ EON™ Microplate Spectrophotometers, Fisher Scientific, USA). The percentage of cell viability was calculated as follows:

\[
\text{Cell viability} \% = \frac{\text{Average absorbance of treated cells}}{\text{average absorbance of untreated cells (control)}} \times 100
\]

EC₅₀ values were generated from GraphPad Prism 7 software (Graphpad Software, La Jolla, CA, USA) with non-linear regression curve fits of the data, where EC₅₀ value was the venom concentration required to reduce cell viability by at least 50% of the cell population. The overall EC₅₀ from the cytotoxic assay was calculated based on EC₅₀ values from 3 independent experiments at 72 h. The cytotoxic assay was performed on the crude, fractions, subfractions and purified proteins of the venom. The anti-proliferative activity was performed using MTT assay at three time points; 24, 48, and 72 h to determine the time- and dose-dependent effect.

### 4.6. Selectivity Index

The degree of selectivity of the purified proteins towards cancer cells was determined by its selectivity index value, which was adapted from studies by Popiolkiewicz et al., (2005) [34] and Chew et al., (2012) [35] and calculated from EC₅₀ values obtained from the treatment of the purified proteins on colon cancer cell lines and normal colon cells. The index value was calculated using the following formula:

\[
\text{selectivity index (SX)} = \frac{\text{EC₅₀ normal colon cell line}}{\text{EC₅₀ colon cancer cell line}} \times 100
\]

Selectivity index value above 100 indicates a high cytotoxic selectivity of the purified proteins towards cancer cells compared to normal cells.

### 4.7. Purification of LAAO from C. purpureomaculatus Crude Venom

Fifty mg of crude venom was dissolved in Milli-Q water and later being centrifuged at 1,000 rpm for 5 min. Supernatants were collected and loaded into a C 26/100 column (GE Healthcare Life Sciences, Marlborough, MA, USA) that was manually packed with Sephadex G-50 Fine (GE Healthcare Life Sciences, USA) gel filtration medium, and mounted on a Äkta Prime Plus system. The column was equilibrated with 0.05 M ammonium acetate pH 6.8, which ran at a flow rate of 0.2 mL/min and elution of the peaks were monitored at 208 nm and automatically collected by the system. The collected fractions were pooled for another 3–4 runs and later freeze dried and re-dissolved in Milli-Q water prior use. Freeze-dried fraction 1 of C. purpureomaculatus venom was dissolved in ddH₂O and centrifuged at 10,000 RPM before being loaded into a Jupiter© C-18 semi-preparative reverse-phase column (Phenomenex, Torrance, CA, USA, 10 µ, 300Å, 250 × 10 mm) mounted on an Agilent HPLC 1260 Infinity system (Agilent Technologies, Santa Clara, CA, USA). The column was equilibrated with 5% of 90% HPLC-grade acetonitrile with 0.1% formic acid at a flow rate of 1 mL/min and maximum pressure of 200 BAR. All fractions were automatically collected using the
fraction collector. The fractions were eluted from the column with an increasing percentage of 90% acetonitrile in 0.1% formic acid using the following multiple step gradient: 5%, 0–5 min; 20%, 6–16 min; 25%, 17–27 min; 30%, 28–38 min; 35%, 39–49 min; 40%, 50–60 min; 45%, 61–71 min; 50%, 72–82 min; 100%, 83–92 min; and 5%, 93–113 min. LAAO were purified from subfraction 9 at retention time of approximately 54.5 min.

4.8. L-αmino Acid Oxidase Activity Assay

The activity of CP-LAAO was performed through a spectrophotometric microplate assay as described by Kishimoto and Takahashi [36] with modifications. Briefly, the assay was conducted in triplicates of 10 µL/well of enzyme solution and 90 µL/well of substrate solution in a 96-well plate. Reaction mixture contained L-αmino acid (L-leucine) that was serially diluted at a range of 1.56 mM to 100 mM, 2 mM o-Phenyldiamine (OPD), 1 mg/mL of horseradish peroxidase (HRP) (Sigma-Aldrich, St. Louis, MO, USA), and LAAO in a total volume of 100 µL/well of 0.1 M Tris-HCl buffer (pH 7.8). The plate was incubated at 37 °C for 60 min and the reaction was terminated with 50 µL of 2 M HCl. The absorbance was measured by BioTek™ EON™ (Fisher Scientific, USA) microplate reader at 492/630 nm. In the kinetic experiment, absorbance was measured at 420/630 nm at time intervals of 5 min within 1 h at 37 °C. V_max value was obtained from Gen5 Data Analysis Software (version 2.0, BioTek, Winooski, VT, USA) bundled with the spectrophotometer. Michaelis-menten data were generated from GraphPad Prism 7 software (Graphpad Software, La Jolla, CA, USA) from enzyme activity (velocity) against substrate concentration plot.

4.9. In-Solution Tryptic Digestion

Approximately 0.5 mg of total protein was added into 1.5 mL tube and mixed with 25 µL of 100 mM ammonium bicarbonate (ABC), 25 µL of trifluroethanol and 1 µL of 200 mM dithiothreitol (DTT). The mixture was then briefly vortexed, and incubated at 60 °C for 1 h. Next, the protein in the tube was alkylated by adding 4.0 µL of 200 mM iodoacetamide (IAA), briefly vortexed, and incubated at room temperature in the dark (covered with foil) for 1 h. Subsequently, 1 µL of 200 mM DTT was added to the tube and incubated at room temperature in the dark for another 1 h. Milli-Q water and 100 mM ABC were then added to the protein to dilute the protein denaturant and raising the pH to pH 7–9, respectively. Trypsin solution was then added to the tubes on a ratio of 1:50, briefly vortexed and incubated overnight at 37 °C. The following day, 1 µL of formic acid was added to stop the trypsin activity, briefly vortexed, and left in a vacuum concentrator overnight to concentrate the digested proteins. Samples were kept at 20 °C prior to LC-MS/MS analysis.

4.10. Protein Analysis via Nanoflow Liquid Chromatography Coupled with Tandem Mass Spectrometry (Nanoflow-ESI-LC-MS/MS)

Digested peptides from in-solution tryptic digestion were loaded into an Agilent C18 300 Å Large Capacity Chip (Agilent Technologies, Santa Clara, CA, USA) and equilibrated with 0.1% formic acid in water (solution A). The peptides were then eluted from the column with an increasing gradient of 90% acetonitrile in 0.1% formic acid in water (solution B) by the following gradient; 3–50% solution B from 0–30 min, 50–95% solution B from 30–32 min, 95% solution B from 32–39 min and 95–3% solution B from 39–47 min. Q-TOF polarity was set at positive with capillary and fragmenter voltage being set at 2050 V and 300 V, respectively, and 5 L/min of gas flow with a temperature of 300 °C. The intact protein spectrum was analyzed in auto MS mode ranging from 110–3000 m/z for MS scan and 50–3000 m/z for MS/MS scan. The spectrum was then analyzed with Agilent MassHunter data acquisition software (version B.07.00, Agilent Technologies, Santa Clara, CA, USA) and then PEAKS 7.0 software (Bioinformatics Solutions Inc., Waterloo, ON, Canada).
4.11. Venom Protein and Peptide Identification by Automated de novo Sequencing (PEAKS Studio) and Data Analysis

Protein identification by automated de novo sequencing was performed using PEAKS Studio 7.0 (Bioinformatics Solution, Waterloo, ON, Canada). The SwissProt Serpentes database was used for protein identification and homology search by comparing the de novo sequence tag. Carbamidomethylation was set as fixed modification with maximum mixed cleavages at three. Parent mass and fragment mass error tolerance were set at 0.1 Da with monoisotopic as the precursor mass search type. Trypsin was selected as the digestion enzyme. False discovery rate (FDR) of 1% and protein score of $-10 \log P > 20$ were used for filtering out inaccurate proteins. PEAKS indicated that a $-10 \log P$ score of greater than 20 was of relatively high in confidence as it targeted very few decoy matches above that threshold.

4.12. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)

SDS-PAGE was performed on a 12% polyacrylamide gel via method that has been previously described (Manns, 2005). SDS-PAGE was performed on a Hoefer SE260 vertical electrophoresis system (Hoefer, Inc. Holliston, MA, USA) until the loading dye front reached the bottom of gel. The gels were then stained with Blue Bandit Protein Stain™ (VWR Life Science AMRESCO, Radnor, PA USA) for 1 h and de-stained with distilled water. The gel was later scanned using a ChemiDoc XRS Imaging System (BioRad, Hercules, CA, USA).

4.13. Quantitative Analysis of Apoptotic Cells

Apoptosis detection was performed using the Annexin-V Apoptosis Detection Kit (Raybiotech Inc., Norcross, GA, USA) following the manufacturer’s instruction with slight modifications. SW480 and SW620 cells were plated and exposed to treatment for 24, 48, and 72 h. Twenty microlitre of the cell suspension were placed in the bottom of a clean 6-well plate and covered with a glass coverslip. Fluorescent detection was observed under an inverted fluorescence microscope (Olympus IX81 Inverted Fluorescence Microscope, Olympus, Shinjuku, Tokyo, Japan) using a dual filter set for FITC (green) and rhodamine (red). A minimum of 200 total targeted cells were counted per sample and the percentage of cells from each population (viable, apoptotic, and necrotic cells) was calculated according to the equation:

$$\% \text{ of cells} = \frac{\text{number of viable or apoptotic or necrotic cells}}{200 \text{ cells}} \times 100$$

The morphological features of the stained cells were distinguished by the bound annexin V-FITC and PI. Apoptotic cells have bound annexin V-FITC and exhibited bright green staining in the plasma membrane and/or bright green and red staining (PI) in the plasma membrane and nuclei, respectively. Necrotic cells showed uniformly red in appearance.

4.14. Quantification of Caspase-3 Activity

Caspase-3 activity was analyzed and performed using the Caspase-3 Colorimetric Assay Kit (Raybiotech Inc., USA), following the manufacturer’s instruction. SW480 and SW620 were plated and exposed to treatment for 24, 48, and 72 h. The intensity of the color was measured at 400 nm by using a microplate spectrophotometer (BioTek™ EON™ Microplate Spectrophotometers, Fisher Scientific, USA). The data was presented in fold-change of absorbance from treated cells against absorbance from untreated cells:

$$\text{Fold change} = \frac{(\text{Abs. reading (400nm) of treated cells})}{(\text{Abs. reading (400nm) of untreated cells})}$$
4.15. Quantification of Bcl-2 Cellular Protein Concentration Using Enzyme-Linked Immunosorbent Assay (ELISA)

Bcl-2 cellular protein concentration was quantified using the Human Bcl-2 Platinum ELISA kit (Affymetrix eBioscience, Vienna, Austria) following the manufacturer’s instruction. Briefly, SW480 and SW620 cells were cultured and treated for 24, 48, and 72 h. The color intensity was measured at 450 nm by using a microplate spectrophotometer (BioTek™ EON™ Microplate Spectrophotometers, Fisher Scientific, USA). Bcl-2 concentrations from the samples were obtained by comparing the absorbance obtained against the standards. Data was presented in fold-change of absorbance from treated cells against absorbance from untreated cells:

\[
\text{Fold – change} = \frac{\text{Abs. reading (400nm) of treated cells}}{\text{Abs. reading (400nm) of untreated cells}}
\]

5. Conclusions

In conclusion, CP-LAAO was purified from the crude venom of C. purpureomaculatus and demonstrated significant cytotoxic activity on SW480 and SW620 cells. Time-dependent analysis revealed that CP-LAAO demonstrated significant anti-proliferative effects at 48 and 72 h. SW480 and SW620 cells treated with CP-LAAO demonstrated significant induction of caspase-3 activity, significant reduction of Bcl-2 levels and classic morphological features that were consistent with apoptosis. Our findings suggest that CP-LAAO has potential anti-cancer activity and may be further investigated as a potential therapeutic agent for the treatment of colon cancer.

Supplementary Materials: The following are available online. Figure S1: SDS-PAGE of purified L-amino acid oxidase (reduced (R) and non-reduced (NR)) aligned with Pierce broad Range Spectra Multicolour protein ladder, Table S1: LC-MS/MS results of purified CP-LAAO, Table S2: Partial peptide sequences of CP-LAAO identified from LC-MS/MS and de novo sequencing, Figure S2: Partial amino acid sequence of C. purpureomaculatus LAAO identified from LCM-MS/MS.

Author Contributions: S.A.Z.A. was responsible for the experimental design, conducted the experiments, analyzed the data and wrote the manuscript. P.R. and M.E.H.C. provided critical feedbacks and approved the manuscript. I.O. analyzed the data and provided critical feedbacks. R.N. contributed in the experimental design, analyzed the data, and provided critical feedbacks for the manuscript.

Funding: This study was financially supported by Fundamental Research Grant Scheme (FRGS) from Ministry of Education, Malaysia (FRGS/2/2014/SKK01/MUSM/01/1).

Acknowledgments: The authors would like to acknowledge Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia for research facilities and support.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Aggarwal, B.B.; Danda, D.; Gupta, S.; Gehlot, P. Models for prevention and treatment of cancer: Problems vs. promises. Biochem. Pharmacol. 2009, 78, 1083–1094. [CrossRef] [PubMed]
2. Bardhan, K.; Liu, K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013, 5, 676–713. [CrossRef] [PubMed]
3. Veettil, S.K.; Lim, K.G.; Chaiyakunapruk, N.; Ching, S.M.; Abu Hassan, M.R. Colorectal cancer in Malaysia: Its burden and implications for a multiethnic country. Asian J. Surg. 2017, 40, 481–489. [CrossRef] [PubMed]
4. Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012, 9, 193–199. [CrossRef] [PubMed]
5. Ciombor, K.K.; Wu, C.; Goldberg, R.M. Recent therapeutic advances in the treatment of colorectal cancer. Annu. Rev. Med. 2015, 66, 83–95. [CrossRef] [PubMed]
6. Souza, D.H.; Eugenio, L.M.; Fletcher, J.E.; Jiang, M.-S.; Garratt, R.C.; Oliva, G.; Selistre-de-Araujo, H.S. Isolation and structural characterization of a cytotoxic L-amino acid oxidase from Agkistrodon contortrix laticinctus snake venom: Preliminary crystallographic data. Arch. Biochem. Biophys. 1999, 368, 285–290. [CrossRef] [PubMed]
7. Stäbeli, R.G.; Sant’Ana, C.D.; Ribeiro, P.H.; Costa, T.R.; Tici, F.K.; Pires, M.G.; Nomizo, A.; Albuquerque, S.; Malta-Neto, N.R.; Marins, M.; et al. Cytotoxic l-amino acid oxidase from Bothrops moojeni: Biochemical and functional characterization. *Int. J. Biol. Macromol.* **2007**, *41*, 132–140. [CrossRef] [PubMed]

8. Alves, R.M.; Antonucci, G.A.; Paiva, H.H.; Cintra, A.C.O.; Franco, J.J.; Mendonça-Franqueiro, E.P.; Dorta, D.J.; Giglio, J.R.; Rosa, J.C.; Fuly, A.L.; et al. Evidence of caspase-mediated apoptosis induced by l-amino acid oxidase isolated from Bothrops atrox snake venom. *Comp. Biochem. Physiol. A Mol. Integr. Physiol.* **2008**, *151*, 542–550. [CrossRef] [PubMed]

9. Zhang, L.; Wei, L.J. Actx-8, a cytotoxic l-amino acid oxidase isolated from Agkistrodon acutus snake venom, induces apoptosis in hela cervical cancer cells. *Life Sci.* **2007**, *80*, 1189–1197. [CrossRef] [PubMed]

10. Samel, M.; Vija, H.; Rönnholm, G.; Siigur, J.; Kalkkinen, N.; Siigur, E. Isolation and characterization of an apoptotic and platelet aggregation inhibiting l-amino acid oxidase from *Vipera berus berus* (common viper) venom. *Biochim. Biophys. Acta Proteins Proteom.* **2006**, *1764*, 707–714. [CrossRef] [PubMed]

11. Wei, J.-F.; Yang, H.-W.; Wei, X.-L.; Wang, W.-Y.; He, S.-H. Purification, characterization and biological activities of the l-amino acid oxidase from *Bungarus fasciatus* snake venom. *Toxicol* **2009**, *54*, 262–271. [CrossRef] [PubMed]

12. Bregge-Silva, C.; Nonato, M.C.; de Albuquerque, S.; Ho, P.L.; de Azevedo, I.L.J.; Diniz, M.R.V.; Losmonte, B.; Rucavado, A.; Diaz, C.; Gutiérrez, J.M.; et al. Isolation and biochemical, functional and structural characterization of a novel l-amino acid oxidase from *Lachesis muta* snake venom. *Toxicol* **2012**, *60*, 1263–1276. [CrossRef] [PubMed]

13. Naumann, G.B.; Silva, L.F.; Silva, L.; Faria, G.; Richardson, M.; Evangelista, K.; Kohlhoff, M.; Gontijo, C.M.F.; Navdaev, A.; de Rezende, F.F.; et al. Cytotoxicity and inhibition of platelet aggregation caused by an l-amino acid oxidase from *Bothrops leucurus* venom. *Biochim. Biophys. Acta Gen. Subj.* **2011**, *1810*, 683–694. [CrossRef] [PubMed]

14. Ahn, M.Y.; Lee, B.M.; Kim, Y.S. Characterization and cytotoxicity of l-amino acid oxidase from the venom of king cobra (*Ophiophagus hannah*). *Int. J. Biochem.* **1997**, *29*, 911–919. [CrossRef]

15. Zhang, L.; Wu, W.T. Isolation and characterization of actx-6: A cytotoxic l-amino acid oxidase from *Agkistrodon acutus* snake venom. *Nat. Prod. Res.* **2008**, *22*, 554–563. [CrossRef] [PubMed]

16. Zainal Abidin, S.A.; Rajadurai, P.; Chowdhury, M.E.; Ahmad Rsmili, M.R.; Othman, I.; Naidu, R. Proteomic characterization and comparison of Malaysian *Tropidolaemus wagleri* and *Cryptelytrops purpureomaculatus* venom using shotgun-proteomics. *Toxins* **2016**, *8*, 299. [CrossRef] [PubMed]

17. Ponnudurai, G.; Chung, M.C.; Tan, N.H. Purification and properties of the l-amino acid oxidase from *Bungarus fasciatus* venom. *Biochim. Biophys. Acta Gen. Subj.* **2011**, *1810*, 683–694. [CrossRef] [PubMed]

18. Moustafa, I.M.; Foster, S.; Lyubimov, A.Y.; Vrieling, A. Crystal structure of LAAO from *Calloselasma rhodostoma* with an t-phenylalanine substrate: Insights into structure and mechanism. *J. Mol. Biol.* **2006**, *364*, 991–1002. [CrossRef] [PubMed]

19. UniProt Consortium. Uniprot: The universal protein knowledgebase. *Nucleic Acids Res.* **2017**, *45*, D158–D169.

20. Izidoro, L.F.M.; Sobrinho, J.C.; Mendes, M.M.; Costa, T.R.; Grabner, A.N.; Rodrigues, V.M.; da Silva, S.L.; Zanchi, F.B.; Zuliani, J.P.; Fernandes, C.F.; et al. Snake venom l-amino acid oxidases: Trends in pharmacology and biochemistry. *BioMed. Res. Int.* **2014**, *2014*, 19. [CrossRef] [PubMed]

21. Pawelek, P.D.; Cheah, J.; Coulombe, R.; Machereux, P.; Ghisla, S.; Vrieling, A. The structure of l-amino acid oxidase reveals the substrate trajectory into an enantiomerically conserved active site. *EMBO J.* **2000**, *19*, 4204–4215. [CrossRef] [PubMed]

22. Suhr, S.M.; Kim, D.S. Identification of the snake venom substance that induces apoptosis. *Biochem. Biophys. Res. Commun.* **1996**, *224*, 134–139. [CrossRef] [PubMed]

23. Ali, S.A.; Stoeva, S.; Abbasi, A.; Alam, J.M.; Kayed, R.; Faigle, M.; Neumeister, B.; Voelter, W. Isolation, structural, and functional characterization of an apoptosis-inducing l-amino acid oxidase from leaf-nosed viper (*Eristocophis macmahoni*) snake venom. *Arch. Biochem. Biophys.* **2000**, *384*, 216–226. [CrossRef] [PubMed]

24. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* **2000**, *100*, 57–70. [CrossRef]

25. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* **1972**, *26*, 239–257. [CrossRef] [PubMed]
26. Li Lee, M.; Chung, I.; Yee Fung, S.; Kanthimathi, M.S.; Hong Tan, N. Antiproliferative activity of king cobra (Ophiophagus hannah) venom L-amino acid oxidase. Basic Clin. Pharmacol. Toxicol. 2014, 114, 336–343. [CrossRef] [PubMed]
27. Ande, S.R.; Kommoju, P.R.; Draxl, S.; Murkovic, M.; Macheroux, P.; Ghisla, S.; Ferrando-May, E. Mechanisms of cell death induction by L-amino acid oxidase, a major component of ophidian venom. Apoptosis 2006, 11, 1439-1451. [CrossRef] [PubMed]
28. Sun, L.-K.; Yoshii, Y.; Hyodo, A.; Tsurushima, H.; Saito, A.; Harakuni, T.; Li, Y.-P.; Kariya, K.; Nozaki, M.; Morine, N. Apoptotic effect in the glioma cells induced by specific protein extracted from Okinawa habu (Trimeresurus flavoviridis) venom in relation to oxidative stress. Toxicol. In Vitro 2003, 17, 169–177. [CrossRef] [PubMed]
29. Zhang, L.; Cui, L. A cytotoxin isolated from Agkistrodon acutus snake venom induces apoptosis via fas pathway in A549 cells. Toxicol. In Vitro 2007, 21, 1095-1103. [CrossRef] [PubMed]
30. Gustafsson, A.B.; Gottlieb, R.A. Bcl-2 family members and apoptosis, taken to heart. Am. J. Physiol. Cell Physiol. 2007, 292, C45-C51. [CrossRef] [PubMed]
31. Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Mitochondrial oxidative stress: Implications for cell death. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 143–183. [CrossRef] [PubMed]
32. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [CrossRef] [PubMed]
33. Costa, T.R.; Menaldo, D.L.; Zoccal, K.F.; Burin, S.M.; Aissa, A.F.; Castro, F.A.D.; Faccoli, L.H.; Greggi Antunes, L.M.; Sampaio, S.V. CR-LAAO, an L-amino acid oxidase from Calloselasma rhodostoma venom, as a potential tool for developing novel immunotherapeutic strategies against cancer. Sci. Rep. 2017, 7, 42673. [CrossRef] [PubMed]
34. Popiolkiewicz, J.; Polkowski, K.; Skierski, J.S.; Mazurek, A.P. In vitro toxicity evaluation in the development of new anticancer drugs-genistein glycosides. Cancer Lett. 2005, 229, 67–75. [CrossRef] [PubMed]
35. Chew, A.J.; Abidin, N.Z.; Wahab, N.B.A. Anti-proliferation and anti-migration activities of ten selected zingiberaceae species against MDA-MB-231 cells. J. Med. Plant. Res. 2012, 6, 3711–3723.
36. Kishimoto, M.; Takahashi, T. A spectrophotometric microplate assay for L-amino acid oxidase. Anal. Biochem. 2001, 298, 136–139. [CrossRef] [PubMed]

Sample Availability: Currently, samples of the compounds are not available from the authors.

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).